Pharmacological treatment of obesity
This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant.
| Auteurs principaux: | , |
|---|---|
| Format: | Digital revista |
| Langue: | English |
| Publié: |
Sociedade Brasileira de Endocrinologia e Metabologia
2006
|
| Accès en ligne: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302006000200024 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| id |
oai:scielo:S0004-27302006000200024 |
|---|---|
| record_format |
ojs |
| spelling |
oai:scielo:S0004-273020060002000242006-05-23Pharmacological treatment of obesityMancini,Marcio C.Halpern,Alfredo Obesity Treatment Anfepramone Mazindol Sibutramine Orlistat Rimonabant This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArquivos Brasileiros de Endocrinologia & Metabologia v.50 n.2 20062006-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302006000200024en10.1590/S0004-27302006000200024 |
| institution |
SCIELO |
| collection |
OJS |
| country |
Brasil |
| countrycode |
BR |
| component |
Revista |
| access |
En linea |
| databasecode |
rev-scielo-br |
| tag |
revista |
| region |
America del Sur |
| libraryname |
SciELO |
| language |
English |
| format |
Digital |
| author |
Mancini,Marcio C. Halpern,Alfredo |
| spellingShingle |
Mancini,Marcio C. Halpern,Alfredo Pharmacological treatment of obesity |
| author_facet |
Mancini,Marcio C. Halpern,Alfredo |
| author_sort |
Mancini,Marcio C. |
| title |
Pharmacological treatment of obesity |
| title_short |
Pharmacological treatment of obesity |
| title_full |
Pharmacological treatment of obesity |
| title_fullStr |
Pharmacological treatment of obesity |
| title_full_unstemmed |
Pharmacological treatment of obesity |
| title_sort |
pharmacological treatment of obesity |
| description |
This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant. |
| publisher |
Sociedade Brasileira de Endocrinologia e Metabologia |
| publishDate |
2006 |
| url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302006000200024 |
| work_keys_str_mv |
AT mancinimarcioc pharmacologicaltreatmentofobesity AT halpernalfredo pharmacologicaltreatmentofobesity |
| _version_ |
1756372597092646912 |